Meet 2019?s newest biotech unicorn ? Gossamer Bio ??which is making its debut on Nasdaq Friday with an upsized $276 million offering.
The drug developer ? with a valuation of $1 billion, according to Renaissance Capital ? is run by former Receptos executives, and follows the year?s first unicorn Alector?$ALEC that raised?$176 million?at a $19 midpoint price. Investors are eagerly anticipating the performance of both, with an eye on other IPO?s waiting in line, after a turbulent December ravaged stocks across the boar